Cargando…

Ceftobiprole Perspective: Current and Potential Future Indications

Ceftobiprole combines an excellent spectrum for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) pathogens, with a low/medium MDR risk, and the β-lactams’ safety in frail patients admitted to the hospital in internal medicine wards which may be at high risk of adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lupia, Tommaso, Pallotto, Carlo, Corcione, Silvia, Boglione, Lucio, De Rosa, Francesco Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915564/ https://www.ncbi.nlm.nih.gov/pubmed/33567771 http://dx.doi.org/10.3390/antibiotics10020170

Ejemplares similares

Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective
por: Corcione, Silvia, et al.
Publicado: (2021)

Predictors of mortality in patients with COVID-19 infection in different health-care settings: A retrospective analysis from a CORACLE study group
por: Boglione, Lucio, et al.
Publicado: (2023)

Possible clinical indications of ceftobiprole
por: Barberán, José
Publicado: (2019)

Bacterial and Viral Infections in Liver Transplantation: New Insights from Clinical and Surgical Perspectives
por: Shbaklo, Nour, et al.
Publicado: (2022)

Ceftobiprole for the treatment of pneumonia: a European perspective
por: Liapikou, Adamantia, et al.
Publicado: (2015)

Microbiome in the setting of burn patients: implications for infections and clinical outcomes
por: Corcione, Silvia, et al.
Publicado: (2020)

Beta Lactams Plus Daptomycin Combination Therapy for Infective Endocarditis: An Italian National Survey (BADAS)
por: Corcione, Silvia, et al.
Publicado: (2022)

COVID-19: in the uncertainty, do not try this at home
por: Lupia, Tommaso, et al.
Publicado: (2020)

New cephalosporins for the treatment of pneumonia in internal medicine wards
por: Lupia, Tommaso, et al.
Publicado: (2020)

Safety and tolerability of ceftobiprole
por: Grau, Santiago
Publicado: (2019)

Ceftobiprole for the treatment of pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

Infection Control in the Era of COVID-19: A Narrative Review
por: Shbaklo, Nour, et al.
Publicado: (2021)

Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022)

Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry
por: Lupia, Tommaso, et al.
Publicado: (2022)

Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments
por: Lupia, Tommaso, et al.
Publicado: (2023)

Giardiasis reactivation during severe SARS-CoV-2 infection
por: Lupia, Tommaso, et al.
Publicado: (2021)

Personalized stewardship and interdisciplinarity: key elements of COVID-19
por: Lupia, Tommaso, et al.
Publicado: (2021)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

Exogenous Fungal Endophthalmitis: Clues to Aspergillus Aetiology with a Pharmacological Perspective
por: Lupia, Tommaso, et al.
Publicado: (2020)

Mechanisms of action and antimicrobial activity of ceftobiprole
por: Morosini, María-Isabel, et al.
Publicado: (2019)

Ozone therapy in COVID-19: A narrative review
por: Cattel, Francesco, et al.
Publicado: (2021)

Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury
por: Cattel, Francesco, et al.
Publicado: (2021)

Ceftobiprole: a clinical view
por: Pérez-Crespo, Pedro María Martínez, et al.
Publicado: (2021)

Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic
por: Lupia, Tommaso, et al.
Publicado: (2022)

Antibiotic De-escalation Experience in the Setting of Emergency Department: A Retrospective, Observational Study
por: Corcione, Silvia, et al.
Publicado: (2021)

2019 novel coronavirus (2019-nCoV) outbreak: A new challenge
por: Lupia, Tommaso, et al.
Publicado: (2020)

COVID-19 pneumonia: do not leave the corticosteroids behind!
por: Pinna, Simone Mornese, et al.
Publicado: (2021)

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole
por: Bustos, César, et al.
Publicado: (2010)

Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
por: Lupia, Tommaso, et al.
Publicado: (2022)

Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole
por: Barbour, April, et al.
Publicado: (2010)

Risk factors for invasive aspergillosis in ICU patients with COVID-19: current insights and new key elements
por: Montrucchio, G., et al.
Publicado: (2021)

Putative invasive pulmonary aspergillosis within medical wards and intensive care units: a 4-year retrospective, observational, single-centre study
por: Corcione, Silvia, et al.
Publicado: (2021)

Ceftobiprole: a potential empirical post-operative monotherapy in prosthetic joint infections
por: Duployez, Claire, et al.
Publicado: (2020)

Therapeutic Endoscopic Ultrasound: Current Indications and Future Perspectives
por: Canakis, Andrew, et al.
Publicado: (2023)

Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry
por: De Rosa, Francesco Giuseppe, et al.
Publicado: (2021)

Ampicillin and Ceftobiprole Combination for the Treatment of Enterococcus faecalis Invasive Infections: “The Times They Are A-Changin”
por: Giuliano, Simone, et al.
Publicado: (2023)

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians
por: Principe, Luigi, et al.
Publicado: (2022)

In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
por: Binyamin, Dana, et al.
Publicado: (2018)

Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non‐Asian Subjects
por: Muller, A. E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6l0h4iidcdc8lc4safp5if06mp